Activity of flavone acetic acid (NSC-347512) against solid tumors of mice - PubMed (original) (raw)
- PMID: 3546183
- DOI: 10.1007/BF00179586
Activity of flavone acetic acid (NSC-347512) against solid tumors of mice
T H Corbett et al. Invest New Drugs. 1986.
Abstract
Flavone acetic acid (FAA) is a new antitumor agent that has recently entered Phase I clinical trials. In preclinical studies, we have found that FAA was broadly active against a variety of transplantable solid tumors of mice (colon #51, #07, #10, #26; pancreatic ductal adenocarcinomas #02 and #03; mammary adenocarcinoma #16/C/Adr; M5076 reticulum cell sarcoma and Glasgow's osteosarcoma). FAA was curative for colon adenocarcinoma #10 and pancreatic ductal adenocarcinoma #03. Thus, for the first time an agent has been identified with very broad, perhaps nearly universal solid tumor activity. FAA was also found to be orally active and stable in solution at 37 degrees C for 48 h. FAA was selectively cytotoxic in vitro for solid tumors over leukemias L1210 and P388 (in a soft-agar colony formation assay), thus correlating cellular selectivity in vitro with in vivo antitumor activity. The finding that FAA was active in vitro, established that the agent did not need metabolism (activation) outside the tumor cell. The main drawback of FAA was an unusual 'threshold' behavior in which only a narrow range of doses were active and splitting the dose markedly decreased activity.
Similar articles
- Activity of batracylin (NSC-320846) against solid tumors of mice.
Mucci-LoRusso P, Polin L, Bissery MC, Valeriote F, Plowman J, Luk GD, Corbett TH. Mucci-LoRusso P, et al. Invest New Drugs. 1989 Nov;7(4):295-306. doi: 10.1007/BF00173759. Invest New Drugs. 1989. PMID: 2557298 - Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro.
Chabot GG, Bissery MC, Gouyette A. Chabot GG, et al. Cancer Chemother Pharmacol. 1989;24(5):273-6. doi: 10.1007/BF00304757. Cancer Chemother Pharmacol. 1989. PMID: 2758556 - Interaction between flavone acetic acid (LM-975, NSC 349512) and radiation in Glasgow's osteogenic sarcoma in vivo.
De Neve W, Evelhoch J, Everett C, Simpson N, Bissery MC, Corbett T, Valeriote F. De Neve W, et al. Int J Radiat Oncol Biol Phys. 1990 Jun;18(6):1359-65. doi: 10.1016/0360-3016(90)90309-8. Int J Radiat Oncol Biol Phys. 1990. PMID: 2370185 - Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.
O'Dwyer PJ, Shoemaker D, Zaharko DS, Grieshaber C, Plowman J, Corbett T, Valeriote F, King SA, Cradock J, Hoth DF, et al. O'Dwyer PJ, et al. Cancer Chemother Pharmacol. 1987;19(1):6-10. doi: 10.1007/BF00296246. Cancer Chemother Pharmacol. 1987. PMID: 3545524 Review. - The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.
Goldin A, Venditti JM, Geran R. Goldin A, et al. Invest New Drugs. 1985;3(1):3-21. doi: 10.1007/BF00176819. Invest New Drugs. 1985. PMID: 3886588 Review.
Cited by
- Identification and induction of cytochrome P450s involved in the metabolism of flavone-8-acetic acid in mice.
Pham MH, Rhinn H, Auzeil N, Regazzetti A, Harami DE, Scherman D, Chabot GG. Pham MH, et al. Drug Metab Lett. 2011 Apr;5(2):73-84. doi: 10.2174/187231211795305221. Drug Metab Lett. 2011. PMID: 21457135 Free PMC article. - Editorial: One small molecule: a new way to treat the flu?
Young H. Young H. J Leukoc Biol. 2011 Mar;89(3):327-8. doi: 10.1189/jlb.1010580. J Leukoc Biol. 2011. PMID: 21357247 Free PMC article. - Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action.
Brauer R, Wang LC, Woon ST, Bridewell DJ, Henare K, Malinger D, Palmer BD, Vogel SN, Kieda C, Tijono SM, Ching LM. Brauer R, et al. Neoplasia. 2010 Sep;12(9):755-65. doi: 10.1593/neo.10636. Neoplasia. 2010. PMID: 20824052 Free PMC article. - Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).
Cheng G, Sun J, Fridlender ZG, Wang LC, Ching LM, Albelda SM. Cheng G, et al. J Biol Chem. 2010 Apr 2;285(14):10553-62. doi: 10.1074/jbc.M109.065631. Epub 2010 Jan 29. J Biol Chem. 2010. PMID: 20118240 Free PMC article. - Vascular disrupting agents in clinical development.
Hinnen P, Eskens FA. Hinnen P, et al. Br J Cancer. 2007 Apr 23;96(8):1159-65. doi: 10.1038/sj.bjc.6603694. Epub 2007 Mar 20. Br J Cancer. 2007. PMID: 17375046 Free PMC article. Review.
References
- Adv Pharmacol Chemother. 1984;20:1-20 - PubMed
- Cancer Res. 1984 Feb;44(2):717-26 - PubMed
- Cancer Chemother Pharmacol. 1981;6(3):253-64 - PubMed
- J Natl Cancer Inst. 1977 Apr;58(4):941-7 - PubMed
- Cancer Res. 1981 Apr;41(4):1281-7 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous